Overview
SLU-PP-332 is a synthetic pan-agonist targeting estrogen-related receptors (ERRα/β/γ). Research using murine models demonstrates its capacity to activate aerobic-exercise gene programming, enhance mitochondrial function, and improve endurance and cardiometabolic outcomes. Critical: No human trials have been conducted as of November 2025. This is exclusively preclinical research material.
Key Specifications
– Vial Size: 5 mg
– Evidence Base: Murine studies only; intraperitoneal administration (25–50 mg/kg twice daily)
– Reconstitution: Add 3.0 mL bacteriostatic water → approximately 1.67 mg/mL
– Measurement: 1 unit on U-100 insulin syringe ≈ 16.7 micrograms
Dosing Protocol (Murine-Equivalent)
| Phase | Daily Dose | Per-Injection Dose | Units per Injection |
|---|---|---|---|
| Weeks 1–2 | 1250 mcg | 625 mcg | 37.5 units (0.375 mL) |
| Weeks 3–8 | 2500 mcg | 1250 mcg | 75 units (0.75 mL) |
Administration: Twice daily at consistent intervals; published research used intraperitoneal route (not subcutaneous).
Reconstitution Instructions
1. Draw 3.0 mL bacteriostatic water with sterile syringe
2. Inject slowly along vial wall to minimize foaming
3. Gently swirl until dissolved (avoid shaking)
4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light
Storage
– Lyophilized: −20 °C (−4 °F) in dry, dark conditions
– Reconstituted: 2–8 °C (35.6–46.4 °F); avoid freeze-thaw cycles
– Allow vials to warm before opening to reduce condensation
Supplies Needed (8-Week Protocol)
– SLU-PP-332 vials: ~25 units
– U-100 insulin syringes: ~112 units
– Bacteriostatic water (10 mL bottles): ~8 units
– Alcohol swabs (100-count): ~3 boxes
Mechanism of Action
SLU-PP-332 functions as an “exercise mimetic” by activating metabolic pathways normally engaged during physical training. In murine studies, it increased mitochondrial respiration, enhanced fatty-acid oxidation in skeletal muscle, and improved aerobic capacity without requiring mechanical exercise stress.
Preclinical Findings
Metabolic Effects: Enhanced mitochondrial function, increased fatty-acid oxidation, improved glucose tolerance in diet-induced obese mice
Cardiac Benefits: Ameliorated heart failure markers through enhanced cardiac fatty-acid metabolism
Endurance: Increased treadmill running capacity and muscle oxidative capacity
Renal Support: Reversed mitochondrial dysfunction in aging kidney models
Administration Technique
– Cleanse vial stopper and injection site with alcohol; allow complete drying
– For subcutaneous injection: pinch skin fold; insert needle at 45–90° angle
– Do not aspirate before injection; deliver slowly and steadily
– Rotate sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy
Note: Published studies used intraperitoneal route; subcutaneous administration is not validated for this compound.
Important Warnings
– No human safety data exists for SLU-PP-332
– Not approved for human consumption
– Research purposes only
– Use new sterile syringes for each administration; dispose in sharps container
– Document all administration times, doses, and observations
– This compound has never been tested in human subjects
Research Considerations
Environmental factors influencing outcomes include diet composition (standard vs. high-fat), housing conditions, and temperature control. The compound was studied alongside exercise training in some models, suggesting potential synergistic effects. Proper handling and compound stability protocols are critical for reproducible research results.
Disclaimer: This content serves educational purposes exclusively and does not constitute medical advice or treatment recommendations. SLU-PP-332 remains a preclinical research compound with no established human safety or efficacy profile.